Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BIBW 2992 (Gilotrif) in Advanced Solid Tumors
NCT02171728Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2004
- Primary completion
- Sep 2006
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of afatinib in solid tumor, sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 168 days and Adverse Events up to 23 months. Started Nov 2004; status: completed.
02
Drugs
afatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02171728.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171728.